Evidence map›Paper›PMID 37546418›Full record

ArticleFrontiers in oncology2023

Calcineurin-independent NFATc1 signaling is essential for survival of Burkitt lymphoma cells.

Krisna Murti, Hendrik Fender, Carolin Glatzle, Rhoda Wismer, Salvador Sampere-Birlanga, Vanessa Wild, Khalid Muhammad, Andreas Rosenwald, Edgar Serfling, Andris Avots

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Krisna MurtiDepartment of Molecular Pathology, Institute of Pathology, and Comprehensive Cancer Center Mainfranken, Julius-Maximilians University of Wuerzburg, Wuerzburg, Germany.
Hendrik FenderDepartment of Molecular Pathology, Institute of Pathology, and Comprehensive Cancer Center Mainfranken, Julius-Maximilians University of Wuerzburg, Wuerzburg, Germany.
Carolin GlatzleDepartment of Molecular Pathology, Institute of Pathology, and Comprehensive Cancer Center Mainfranken, Julius-Maximilians University of Wuerzburg, Wuerzburg, Germany.
Rhoda WismerDepartment of Molecular Pathology, Institute of Pathology, and Comprehensive Cancer Center Mainfranken, Julius-Maximilians University of Wuerzburg, Wuerzburg, Germany.
Salvador Sampere-BirlangaDepartment of Molecular Pathology, Institute of Pathology, and Comprehensive Cancer Center Mainfranken, Julius-Maximilians University of Wuerzburg, Wuerzburg, Germany.
Vanessa WildDepartment of Molecular Pathology, Institute of Pathology, and Comprehensive Cancer Center Mainfranken, Julius-Maximilians University of Wuerzburg, Wuerzburg, Germany.
Khalid MuhammadDepartment of Molecular Pathology, Institute of Pathology, and Comprehensive Cancer Center Mainfranken, Julius-Maximilians University of Wuerzburg, Wuerzburg, Germany.
Andreas RosenwaldDepartment of Molecular Pathology, Institute of Pathology, and Comprehensive Cancer Center Mainfranken, Julius-Maximilians University of Wuerzburg, Wuerzburg, Germany.
Edgar SerflingDepartment of Molecular Pathology, Institute of Pathology, and Comprehensive Cancer Center Mainfranken, Julius-Maximilians University of Wuerzburg, Wuerzburg, Germany.
Andris AvotsDepartment of Molecular Pathology, Institute of Pathology, and Comprehensive Cancer Center Mainfranken, Julius-Maximilians University of Wuerzburg, Wuerzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Burkitt lymphoma (BL), a tumor of germinal center B cells, the pro-apoptotic properties of MYC are controlled by tonic B cell receptor (BCR) signals. Since BL cells do not exhibit constitutive NF-

Indexed as

activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL)apoptosisB cell receptor (BCR)Burkitt lymphomaBurkitt lymphoma (BL)cyclosporin ANFATc1nuclear localization

Identifiers

PMID37546418
PMCPMC10403262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.